To truly discover Rising Stars in a rapidly changing landscape that may no longer recognise traditional metrics – publication numbers, qualifications, involvement in trials, etc – with the
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh